Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc.（HRMY）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · HRMY · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
8
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Harmony Biosciences Holdings, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
HRMY 季度内部人买卖趋势
HRMY 内幕交易卖出 · HRMY 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · HRMY CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
HRMY 高管卖出股份 · HRMY 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 1, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option | 18,750 | — | Form 4 |
| May 1, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Other | 8,882 | $283K | Form 4 |
| Apr 7, 2026 | Zaeske Adam H. CHIEF COMMERCIAL OFFICER | Option | 7,500 | — | Form 4 |
| Apr 7, 2026 | Zaeske Adam H. CHIEF COMMERCIAL OFFICER | Other | 3,173 | $88K | Form 4 |
| Jan 26, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale | 3,746 | $139K | Form 4 |
| Jan 25, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option | 4,725 | — | Form 4 |
| Jan 24, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option | 3,813 | — | Form 4 |
| Jan 25, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Other | 2,553 | $94K | Form 4 |
| Jan 24, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Other | 2,239 | $82K | Form 4 |
| Jan 25, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Option | 2,600 | — | Form 4 |
| Jan 24, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Option | 2,500 | — | Form 4 |
| Jan 25, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Other | 1,126 | $41K | Form 4 |
| Jan 24, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Other | 1,116 | $41K | Form 4 |
| Jan 25, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option | 2,662 | — | Form 4 |
| Jan 24, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option | 2,188 | — | Form 4 |
| Jan 25, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Other | 1,372 | $51K | Form 4 |
| Jan 24, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Other | 1,153 | $42K | Form 4 |
| Jan 25, 2026 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Option | 13,000 | — | Form 4 |
| Jan 24, 2026 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Option | 10,500 | — | Form 4 |
| Jan 25, 2026 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Other | 5,654 | $208K | Form 4 |
| Jan 24, 2026 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Other | 4,785 | $176K | Form 4 |
| Jan 15, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale | 20,961 | $753K | Form 4 |
| Dec 12, 2025 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Option | 20,000 | $164K | Form 4 |
| Dec 12, 2025 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Sale | 5,933 | $238K | Form 4 |
| Dec 5, 2025 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option | 20,000 | $581K | Form 4 |
Dayno Jeffrey M.
PRESIDENT, CEO · Director
日期
Dec 12
股数
20,000
均价
$8.22
总金额
$164K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 HRMY 内幕交易
HRMY 内幕交易
Harmony Biosciences Holdings, Inc.（HRMY）内幕交易数据来源于公司内部人（包括Kapadia Sandip (CHIEF FINANCIAL OFFICER), Budur Kumar (CHIEF MEDICAL OFFICER), Dayno Jeffrey M. (PRESIDENT, CEO · Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。HRMY内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Harmony Biosciences Holdings, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
HRMY 内幕交易 · 5个问题Harmony Biosciences Holdings, Inc.（HRMY）的内部人包括高管和董事，如Kapadia Sandip (CHIEF FINANCIAL OFFICER), Budur Kumar (CHIEF MEDICAL OFFICER), Dayno Jeffrey M. (PRESIDENT, CEO · Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026